Big data for better outcomes, policy innovation and healthcare system transformation
DO-IT logo


Start Date
End Date
Grant agreement number

IMI Funding
3 549 833
EFPIA in kind
3 604 817
37 105
Total Cost7 191 755


Institutions across Europe house rich databases with detailed personal and biological information. If linked, this ‘big data’ has the potential to deliver insights that will allow healthcare systems to ensure that the patient is truly at the centre of decision-making, with outcomes that matter and resources focused on treatments that really make a difference. IMI’s Big Data for Better Outcomes (BD4BO) programme is generating knowledge, data and methodologies needed to support the transition towards more outcomes-focused, sustainable healthcare systems in Europe. Through its projects, the programme focuses on a number of key therapeutic areas, namely Alzheimer’s disease, heart disease, and certain cancers.

The DO>IT project was launched to provide a coordination platform for the BD4BO programme, exploiting synergies across the projects and maximising its impact on healthcare systems. Specially, DO>IT will aggregate learnings and disseminate findings from the projects; develop minimum data privacy standards; engage with key stakeholders; and recommend areas for future collaborative research.

Participants Show participants on map

EFPIA companies
  • Amgen NV, Brussels, Belgium
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Boehringer Ingelheim International GmbH, Ingelheim, Germany
  • Celgene International II Sarl, Couvet, Switzerland
  • Eli Lilly and Company Ltd, Basingstoke, United Kingdom
  • European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium
  • F. Hoffmann-La Roche Ltd, Basel, Switzerland
  • Glaxosmithkline Research And Development LTD, Brentford, Middlesex, United Kingdom
  • Health iQ LTD., London, United Kingdom
  • Institut De Recherches Internationales Servier, Suresnes, France
  • Janssen Pharmaceutica NV, Beerse, Belgium
  • Merck KGaA, Darmstadt, Germany
  • Merck Sharp & Dohme Corp., Whitehouse Station, New Jersey, United States
  • Novartis Pharma AG, Basel, Switzerland
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Research and Development, Chilly Mazarin, France
  • UCB Biopharma SPRL, Brussels, Belgium
  • Verband forschender Arzneimittelhersteller e.V., Berlin, Germany
Universities, research organisations, public bodies, non-profit groups
  • Asociacion Nacional Empresarial de la Industria Farmacéutica, Madrid, Spain
  • Bocconi University, Milan, Italy
  • Imperial College of Science, Technology and Medicine, London, United Kingdom
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
  • InterSystems GmbH, Darmstadt, Germany
  • London School of Economics and Political Science, London, United Kingdom
  • National Institute for Health and Care Excellence, Manchester, United Kingdom
  • Norwegian Institute of Public Health, Oslo, Norway
  • Semmelweis University, Budapest, Hungary
  • Tandvårds- och Läkemedelsförmånsverket, Stockholm, Sweden
  • Technologie- und Methodenplattform für die vernetzte medizinische Forschung e. V., Berlin, Germany
  • The Association of the British Pharmaceutical Industry, London, United Kingdom
  • The Swedish Institute for Health Economics, Lund, Sweden
Patient organisations
  • European Cancer Patient Coalition, Brussels, Belgium
  • European Multiple Sclerosis Platform, Brussels, Belgium
Associated partners
  • Norwegian Medicines Agency, Oslo, Norway


Project coordinator
Elias Mossialos
London School of Economics and Political Science